the absolute excess risk of stroke in patients older than age 75 years receiving thrombolytic treatment was <1%, and there was no age-associated excess in the risk of other major bleeding ...

In total, two hundred and thirty-five patients were diagnosed with ischemic stroke, of which eighty-two patients received thrombolytic treatment. Ultimately, eighty-eight interviews were conducted ...

and 8,769 with a right-sided stroke (P <0.0001). Fifty-eight percent of patients who received thrombolytic treatment had suffered a left-hemispheric stroke, and a larger proportion of left ...

Biogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance on an old treatment approach – using clot-busting thrombolytic drugs to treat ischaemic stroke. T ...

It has now been 25 years since prourokinase was in the spotlight as a potential treatment for acute ischaemic stroke. In 1999, the PROACT-II randomised controlled trial compared intra-arterial ...

In the early 1990s, a pivotal randomised trial sponsored by the National Institute of Neurological Disorders and Stroke ...

The following is a summary of "Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, ...